

McHutchison John G
Form 3
April 27, 2018

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

McHutchison John G

(Last) (First) (Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

04/23/2018

3. Issuer Name **and** Ticker or Trading Symbol
GILEAD SCIENCES INC [GILD]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer ☐ Other
(give title below) (specify below)
Chief Scientific Off/HeadR&D

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person

GILEAD SCIENCES,
INC., 333 LAKESIDE DRIVE

(Street)

FOSTER CITY, CA 94404

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

22,906

D

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)
Title

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: McHutchison John G - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Non-qualified Stock Option (Right to Buy)	Â <u>(1)</u>	07/22/2020	Common Stock	19,950	\$ 16.89	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	01/26/2022	Common Stock	16,850	\$ 24.295	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/01/2023	Common Stock	29,710	\$ 40.56	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/01/2024	Common Stock	42,290	\$ 80.65	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/01/2025	Common Stock	51,690	\$ 104.83	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/01/2026	Common Stock	58,950	\$ 84.05	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/02/2027	Common Stock	63,590	\$ 72.25	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(2)</u>	02/01/2028	Common Stock	62,910	\$ 83.49	D	Â
Restricted Stock Unit	Â <u>(3)</u>	Â <u>(3)</u>	Common Stock	2,930	\$ <u>(4)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McHutchison John G GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404	Â	Â	Â Chief Scientific Off/HeadR&D	Â

Signatures

/s/ Marissa Song by Power of Attorney for John G
McHutchison

04/27/2018

 Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (2) The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- (3) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Edgar Filing: McHutchison John G - Form 3

(4) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.